Participated · Series B · Aug 2026

Meduloc develops an FDA-cleared, sterile, single-use flexible nitinol intramedullary implant and delivery system for long-bone fracture applications in adult and pediatric patients. The platform is positioned to provide fracture stability while preserving anatomy and avoiding joint violation in certain applications. Following regulatory clearance, the company is moving into controlled commercialization and plans an alpha launch in early August 2026 with select surgeons and institutions to build clinical experience and collect feedback. Meduloc intends to use recently raised capital to generate additional clinical evidence and to build the commercial infrastructure required for broader adoption. The company is headquartered in West Chester, Pennsylvania, and has attracted regional investor support from Greater Philadelphia and statewide life-sciences funding organizations.

Participated · Seed · Mar 2024

Zenapse is a Westport, CT–based martech company that offers an AI SaaS marketing and customer experience optimization platform. Its core product, ZenImpact, is built on a large Emotion Model (LEM) knowledge graph that uses AI to interpret signals from more than 150 million consumers to surface emotional insights for marketers. The platform enables brands to create emotionally intelligent marketing experiences and counts customers such as Sam’s Club, Aeropostale, Prosper, and Bread Financial. The company was founded by Matthew Bernardini, Janis Nakano Spivack, Godfrey Baker, and Christer Manning. Zenapse plans to use the new funding to further develop its AI technology, expand product features, integrate with more platforms, scale its customer base, and enhance its marketing efforts. Financially, Zenapse has raised $8.0M in a seed round led by Naples Technology Ventures with participation from Ben Franklin Technology Partners, Broad Street Angels, and BaseCamp Ventures.

Participated · Seed · Mar 2024

Smart Response Technologies (SRT) develops Delphini, a cloud-based AI SaaS platform that provides real-time voice-to-text transcriptions for emergency call takers and dispatchers. Delphini was developed in cooperation with the Air Force Research Lab and offers features like spatially separated audio, customizable keyword highlights, and predictor-word detection. The company says Delphini increases first-responder communications effectiveness by 55% and comprehension by 70% while helping reduce stress and burnout. Delphini is already used by police and fire departments and county 911 Emergency Communications Centers nationwide and supports command-and-control centers, corrections, event management, and campus and corporate security. SRT is veteran-owned, founded in 2022, and plans to use new capital to accelerate product development, expand R&D, and broaden its offerings. The company has emphasized its social impact and potential for collaborations with other firms in the public safety sector.

Participated · Seed · Feb 2022

Lula builds a zero-commission, multi-vendor 30-minute delivery platform that helps convenience stores, pharmacies and consumer packaged goods brands publish thousands of SKUs and syndicate them across major third-party delivery companies. The product aggregates orders from multiple delivery providers into one synchronous tool for merchants with one or two employees. Lula charges a monthly subscription (which the company says most stores break even on within the first couple days of the month) rather than a commission. The company was started in late 2020 after founders encountered pandemic-driven store closures and has helped hundreds of stores onboard to delivery. Lula is growing store count by over 30% month-over-month, is in talks with large convenience store chains in Europe and Mexico, and is receiving organic inbound from independents across the U.S. The company has 35 employees and plans to use new funding for product development and to expand sales and customer success headcount as it scales to all 50 states and targets the next 2,000 customers. Lula digitizes convenience-store inventories, supplies stores with tablets and sustainable packaging, and syndicates their listings to major delivery platforms (DoorDash, Grubhub, Uber Eats and its own platform). The company shifted from hiring its own eco-conscious drivers to partnering with third-party delivery services and charging stores a $50–$99 monthly subscription instead of commissions. Lula operates in New York, New Jersey, Florida and Philadelphia, and says partnering stores have seen a roughly 30% increase in revenue within a 10-mile radius. The team comprises seven full-time and eight part-time staffers, and the company donates 1% of sales to 1% for the Planet. Lula plans senior hires in the Philadelphia area and aims to expand with larger convenience store chains and to onboard stores remotely across all 50 states.

Participated · Series A · Jan 2022

Strados Labs builds smart sensor platforms that combine machine learning and proprietary algorithms to provide early detection and predictions of worsening respiratory diseases. Its flagship product is RESP™, a respiratory-health smart sensor platform that has received CE Mark and FDA Class II 510(k) clearance. The company is developing a pipeline of additional smart sensor platforms to support chronic disease management and plans to add heart failure in late 2022. Strados will continue to target asthma, COPD and infectious respiratory diseases including COVID and RSV. Recent commercial milestones include key contracts with major pharmaceutical partners for use in decentralized trials and the submission of four abstracts to the American Thoracic Society. The company raised $4.5M in a pre-Series A round to support these efforts and recent commercial expansion. Strados Labs has developed RESP, a thin, adhesive wearable that records 30-second chest sound samples every 15 minutes and transmits them via a smartphone app to the cloud for physician review. RESP uses noise-cancelling algorithms and filters to focus on internal lung sounds and is described by clinicians as a “Holter for the lungs.” The company is commercialized, has been generating revenue, and has partnerships with pharmaceutical companies and health systems. Strados holds FDA 510(k) clearance for RESP for use in healthcare settings, though an additional clearance will be required to ship devices directly for in-home monitoring. The company maintains a database of more than 150,000 breath sounds and aims to grow that to 1 million in the next six months to validate algorithms across noisy real-world settings. Strados is Philadelphia-based and is positioning RESP for decentralized clinical trials, hospital-at-home, and broader remote-care reimbursement expansion.